Anemia (low numbers of red blood cells) is a serious complication of chronic renal failure and use of certain drugs such as chemotherapy in cancer patients. Erythropoietin (EPO) stimulates production of red blood cells, and recombinant EPO products have annual sales of about $6 billion, primarily for treating anemia. BBT-021 is a long-acting EPO ImmunoFusion Protein that is significantly more potent than EPO at stimulating red blood cell formation in animals.
Advanced Protein Engineering
 |
2425 55th Street, Suite 210 Boulder, CO 80301 |  |
303-420-4420 |
